CHOLESTOSOME Trademark

Trademark Overview


On Thursday, September 1, 2016, a trademark application was filed for CHOLESTOSOME with the United States Patent and Trademark Office. The USPTO has given the CHOLESTOSOME trademark a serial number of 87158910. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, October 29, 2018. This trademark is owned by TheraHoldings AG. The CHOLESTOSOME trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for Alzheimer's disease, Parkinson's disease, bacterial infections, viral infections, fungal infections, sepsis, psoriasis, sunburn and thermal injury to skin and underlying tissues, lung, asthma, chronic obstructive pulmonary disease (COPD), emphysema, cancer of any or all types, diabetes, hepatic diseases including hepatitis b or c, hepatic disease including non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), metabolic syndrome diseases, genetic disorders, Fabry's disease, alpha 1 anti-trypsin deficiency, hemophilia, cystic fibrosis, and cancers of all types, systemic inflammatory diseases including inflammatory bowel diseases, Crohn's disease, rheumatoid arthritis, Systemic lupus erythematosus (SLE), ankylosing spondylitis and vaccines and vaccination to prevent or treat infectious diseases and cancer; pharmaceutical preparations, namely, lipid vesicles encapsulating pharmaceuticals for the treatment of Alzheimer's disease, P...
cholestosome

General Information


Serial Number87158910
Word MarkCHOLESTOSOME
Filing DateThursday, September 1, 2016
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, October 29, 2018
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, January 31, 2017

Trademark Statements


Goods and ServicesPharmaceutical preparations for Alzheimer's disease, Parkinson's disease, bacterial infections, viral infections, fungal infections, sepsis, psoriasis, sunburn and thermal injury to skin and underlying tissues, lung, asthma, chronic obstructive pulmonary disease (COPD), emphysema, cancer of any or all types, diabetes, hepatic diseases including hepatitis b or c, hepatic disease including non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), metabolic syndrome diseases, genetic disorders, Fabry's disease, alpha 1 anti-trypsin deficiency, hemophilia, cystic fibrosis, and cancers of all types, systemic inflammatory diseases including inflammatory bowel diseases, Crohn's disease, rheumatoid arthritis, Systemic lupus erythematosus (SLE), ankylosing spondylitis and vaccines and vaccination to prevent or treat infectious diseases and cancer; pharmaceutical preparations, namely, lipid vesicles encapsulating pharmaceuticals for the treatment of Alzheimer's disease, Parkinson's disease, bacterial infections, viral infections, fungal infections, sepsis, psoriasis, sunburn and thermal injury to skin and underlying tissues, lung, asthma, chronic obstructive pulmonary disease (COPD), emphysema, cancer of any or all types, diabetes, hepatic diseases including hepatitis b or c, hepatic disease including non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), metabolic syndrome diseases, genetic disorders, Fabry's disease, alpha 1 anti-trypsin deficiency, hemophilia, cystic fibrosis, and cancers of all types, systemic inflammatory diseases including inflammatory bowel diseases, Crohn's disease, rheumatoid arthritis, Systemic lupus erythematosus (SLE), ankylosing spondylitis and vaccines and vaccination to prevent or treat infectious diseases and cancer; pharmaceutical preparations, namely, vesicles made of cholesteryl ester and containing pharmaceuticals for use in the treatment of Alzheimer's disease, Parkinson's disease, bacterial infections, viral infections, fungal infections, sepsis, psoriasis, sunburn and thermal injury to skin and underlying tissues, lung, asthma, chronic obstructive pulmonary disease (COPD), emphysema, cancer of any or all types, diabetes, hepatic diseases including hepatitis b or c, hepatic disease including non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), metabolic syndrome diseases, genetic disorders, Fabry's disease, alpha 1 anti-trypsin deficiency, hemophilia, cystic fibrosis, and cancers of all types, systemic inflammatory diseases including inflammatory bowel diseases, Crohn's disease, rheumatoid arthritis, Systemic lupus erythematosus (SLE), ankylosing spondylitis, and vaccines and vaccination to prevent or treat infectious diseases and cancer

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, September 8, 2016
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameTheraHoldings AG
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
Address8835 Feusisberg
CH

Party NameTheraHoldings AG
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
Address8835 Feusisberg
CH

Trademark Events


Event DateEvent Description
Monday, October 29, 2018ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED
Monday, October 29, 2018ABANDONMENT - NO USE STATEMENT FILED
Tuesday, March 20, 2018NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, March 16, 2018EXTENSION 2 GRANTED
Friday, March 16, 2018EXTENSION 2 FILED
Friday, March 16, 2018TEAS EXTENSION RECEIVED
Tuesday, September 5, 2017NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, September 1, 2017EXTENSION 1 GRANTED
Friday, September 1, 2017EXTENSION 1 FILED
Friday, September 1, 2017TEAS EXTENSION RECEIVED
Monday, May 1, 2017ASSIGNED TO EXAMINER
Tuesday, March 28, 2017NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, January 31, 2017OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, January 31, 2017PUBLISHED FOR OPPOSITION
Wednesday, January 11, 2017NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Monday, December 19, 2016APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, December 14, 2016EXAMINER'S AMENDMENT ENTERED
Wednesday, December 14, 2016NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Wednesday, December 14, 2016EXAMINERS AMENDMENT E-MAILED
Wednesday, December 14, 2016EXAMINERS AMENDMENT -WRITTEN
Saturday, December 10, 2016ASSIGNED TO EXAMINER
Thursday, September 8, 2016NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Monday, September 5, 2016NEW APPLICATION ENTERED IN TRAM